Tuesday - December 24, 2024
GSK: Blenrep Combination Accepted for Priority Review in China in Relapsed/refractory Multiple Myeloma
December 11, 2024
LONDON, England, Dec. 11 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 9, 2024:

* * *

- Regulatory submission supported by phase III head-to-head DREAMM-7 trial showing statistically significant efficacy, including overall survival

- If approved, Blenrep combination could redefine multiple myeloma treatment at or after first relapse

- Seventh major regulatory filing acceptance . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products